According to Wu et al., the EV released by EGFR wild type NSCLC cells promote osimertinib resistance in NSCLC cells carrying EGFR mutation [76], suggesting that tumor heterogeneity is critical in treatment refractoriness. The gene discussed is EGFR; the disease is neoplasm.